Under the ATM equity offering sales agreement, sales of common stock, if any, through Further Lane, will be made by means of ordinary brokers' transactions, in privately negotiated transactions, or otherwise, at market prices prevailing at the time of sales, prices related to prevailing market prices or negotiated prices.
The common stock will be offered under the company's existing effective shelf registration statement (including a prospectus) filed with the
A copy of the prospectus supplement and accompanying prospectus relating to these securities may be obtained by contacting
This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor may there be any sale of Sarepta's common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any state or jurisdiction.
About
Forward-Looking Statements and Information
This news release contains forward-looking statements regarding the company's offering from time to time of common stock and the associated use of proceeds, and is based on the company's current expectations and judgment. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements.
These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Known risk factors include, among others: market conditions; clinical trials may not demonstrate safety and efficacy of any of Sarepta's drug candidates and/or Sarepta's antisense-based technology platform; development of any of Sarepta's drug candidates may not result in funding from the U.S. government in the anticipated amounts or on a timely basis, if at all; scale-up of manufacturing may not be successful and any of Sarepta's drug candidates may fail in development, may not receive required regulatory approvals (including Subpart H accelerated approval), or be delayed to a point where they do not become commercially viable; Sarepta may need additional funds to conduct research and development efforts.
Any of the foregoing risks could materially and adversely affect Sarepta's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the official corporate documents filed with the
Sarepta Investor Contact:
857.242.3714
Email Contact
Sarepta Media Contact:
857.242.3710
Email Contact